Compare Oatly Group AB - ADR (OTLY) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oatly Group AB - ADR vs Sanofi SA — how do they compare? Oatly Group AB - ADR trades at $10.35 (market cap $330.93M), while Sanofi SA trades at $40 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 287.6× Oatly Group AB - ADR's market cap, and Sanofi SA pays a 6.01% dividend while Oatly Group AB - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oatly Group AB - ADR for 18 Days and Sanofi SA for 94 Days on average.
| OTLY | SNY | |
|---|---|---|
Market Cap | $330.93M | $95.18B |
Volume | 68,708 | 2,995,646 |
Sector | Consumer Staples | Health |
52-Week High | $15.91 | $52.34 |
52-Week Low | $8.03 | $39.51 |
Typical Hold Time | 18 Days | 94 Days |
Enterprise Value | $835.34M | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OTLY trades at $10.37, down 1.33% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. Fundamentally, the company shows improving revenue growth ($862M in 2025, projected $925M in 2026) and narrowing losses, though it remains unprofitable with negative cash flow. Analyst sentiment is divided with a $12.28 consensus target, representing 18% upside potential from current levels.
The outlook suggests cautious optimism as Oatly demonstrates operational improvements and revenue acceleration, but significant risks remain including persistent negative cash flow, high debt levels, and competitive pressures in the plant-based beverage market. The stock offers potential for recovery if the company can achieve its projected path toward profitability.
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
